Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Trial Profile

Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2017 Results of a study investigating rationale of low dose Cyclophosphamide to potentiate the anti myeloma activity of Daratumumab through augmentation of macrophage induced ADCP presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results of an interim safety analysis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top